Absence of CD9 enhances adhesion-dependent morphologic differentiation, survival, and matrix metalloproteinase-2 production in small cell lung cancer cells

Cancer Research

Volumn 66, Issue 19, 2006, Pages 9557-9565

  Saito, Yoshiyuki ^a   Tachibana, Isao ^a   Takeda, Yoshito ^a   Yamane, Hiroyuki ^a   He, Ping ^a   Suzuki, Mayumi ^a   Minami, Seigo ^a   Kijima, Takashi ^a   Yoshida, Mitsuhiro ^a   Kumagai, Toru ^a   Osaki, Tadashi ^a   Kawase, Ichiro ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CD9 ANTIGEN; FOCAL ADHESION KINASE; GELATINASE A; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE; TETRASPANIN;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL DIFFERENTIATION; CELL GROWTH; CELL STRUCTURE; CELL SURVIVAL; CONTROLLED STUDY; ENZYME SYNTHESIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SMALL CELL CARCINOMA;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTIGENS, CD; APOPTOSIS; CARCINOMA, SMALL CELL; CELL ADHESION; CELL LINE, TUMOR; CELL SIZE; CELL SURFACE EXTENSIONS; ENZYME INDUCTION; FIBRONECTINS; HUMANS; LUNG NEOPLASMS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-AKT; RECOMBINANT FUSION PROTEINS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 33750301084     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-1131     Document Type: Article

References (33)

1. Aisner J. Extensive-disease small-cell lung cancer: the thrill of victory; the agony of defeat. J Clin Oncol 1996;14:658-65.
2. Brambilla E, Moro D, Gazzeri S, et al. Cytotoxic chemotherapy induces cell differentiation in small-cell lung carcinoma. J Clin Oncol 1991;9:50-61.
3. Sethi T, Rintoul RC, Moore SM, et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med 1999;5:662-8.
4. Moore SM, Rintoul RC, Walker TR, Chilvers ER, Haslett C, Sethi T. The presence of a constitutively active phosphoinositide 3-kinase in small cell lung cancer cells mediates anchorage-independent proliferation via a protein kinase B and p70s6k-dependent pathway. Cancer Res 1998;58:5239-47.
5. Kraus AC, Ferber I, Bachmann SO, et al. In vitro chemo- and radio-resistance in small cell lung cancer correlates with cell adhesion and constitutive activation of AKT and MAP kinase pathways. Oncogene 2002;21:8683-95.
6. Kijima T, Maulik G, Ma PC, Madhiwala P, Schaefer E, Salgia R. Fibronectin enhances viability and alters cytoskeletal functions (with effects on the phosphatidylinositol 3-kinase pathway) in small cell lung cancer. J Cell Mol Med 2003;7:157-64.
7. Tsurutani J, West KA, Sayyah J, Gills JJ, Dennis PA. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy. Cancer Res 2005;65:8423-32.
8. Hemler MH. Tetraspanin functions and associated microdomains. Nat Rev Mol Cell Biol 2005;6:801-11.
9. Wright MD, Moseley GW, van Spriel AB. Tetraspanin microdomains in immune cell signalling and malignant disease. Tissue Antigens 2004;64:533-42.
10. Boucheix C, Rubinstein E. Tetraspanins. Cell Mol Life Sci 2001;58:1189-205.
11. Boucheix C, Due GH, Jasmin C, Rubinstein F. Tetraspanins and malignancy. Expert Rev Mol Med 2001;2001:1-17.
12. 1-tetraspanin protein complexes in tumor cell invasion. Evidence for the role of the complexes in production of matrix metalloproteinase 2 (MMP-2). J Cell Biol 1999;146:1375-89.
13. Sawada S, Yoshimoto M, Odintsova E, Hotchin NA, Berditchevski F. The tetraspanin CD151 functions as a negative regulator in the adhesion-dependent activation of Ras. J Biol Chem 2003;278:26323-6.
14. Funakoshi T, Tachibana I, Hoshida Y, et al. Expression of tetraspanins in human lung cancer cells: frequent downregulation of CD9 and its contribution to cell motility in small cell lung cancer. Oncogene 2003;22:674-87.
15. Tachibana I. Bodorova J, Berditchevski F, Zutter MM, Hemler ME. NAG-2, a novel transmembrane-4 superfamily (TM4SF) protein that complexes with integrins and other TM4SF proteins. J Biol Chem 1997;272:29181-9.
16. 1 integrin-mediated morphological differentiation in neuroblastoma and small cell lung cancer cells. Exp Cell Res 1996;227:230-9.
17. Munaut C, Noel A, Hougrand O, Foidart JM, Boniver J, Deprez M. Vascular endothelial growth factor expression correlates with matrix metalloproteinases MT1-MMP, MMP-2 and MMP-9 in human glioblastomas. Int J Cancer 2003;106:848-55.
18. Giancotti FG, Ruoslahti E. Integrin signaling. Science 1999;285:1028-32.
19. Gu J, Fujibayashi A, Yamada KM, Sekiguchi K. Laminin-10/11 and fibronectin differentially prevent apoptosis induced by serum removal via phosphatidylinositol 3-kinase/Akt- and MEK1/ERK-dependent pathways. J Biol Chem 2002;277:19922-8.
20. Kijima T, Maulik G, Ma PC, et al. Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells. Cancer Res 2002;62:6304-11.
21. Bjorklund M, Koivunen E. Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta 2005;1755:37-69.
22. Zheng R, Yano S, Zhang H, et al. CD9 overexpression suppressed the liver metastasis and malignant ascites via inhibition of proliferation and motility of small-cell lung cancer cells in NK cell-depleted SCID mice. Oncol Res 2005;15:365-72.
23. Carney DN, Gazdar AF, Bepler G, et al. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res 1985;45:2913-23.
24. 1 integrin and the neural adhesion molecule L1. J Neurosci Res 1996;43:12-31.
25. 1 integrin-dependent manner. J Neurosci 1997;17:2756-65.
26. Ono M, Handa K, Withers DA, Hakomori S. Motility inhibition and apoptosis are induced by metastasis-suppressing gene product CD82 and its analogue CD9, with concurrent glycosylation. Cancer Res 1999;59:2335-9.
27. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005;4:988-1004.
28. Yokomizo A, Tindall DJ, Drabkin H, et al. PTEN/MMAC1 mutations identified in small cell, but not in non-small cell lung cancers. Oncogene 1998;17:475-9.
29. Arcaro A, Khanzada UK, Vanhaesebroeck B, Tetley TD, Waterfield MD, Seckl MJ. Two distinct phosphoinositide 3-kinases mediate polypeptide growth factor-stimulated PKB activation. EMBO J 2002;21:5097-108.
30. Krystal GW, Sulanke G, Litz J. Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy. Mol Cancer Ther 2002;1:913-22.
31. Hemler ME. Tetraspanin proteins mediate cellular penetration, invasion, and fusion events and define a novel type of membrane microdomain. Annu Rev Cell Dev Biol 2003;19:397-422.
32. Longhurst CM, Jacobs JD, White MM, et al. Chinese hamster ovary cell motility to fibronectin is modulated by the second extracellular loop of CD9. Identification of a putative fibronectin binding site. J Biol Chem 2002;277:32445-52.
33. Liu WM, Cao YJ, Yang YJ, Li J, Hu Z, Duan EK. Tetraspanin CD9 regulates invasion during mouse embryo implantation. J Mol Endocrinol 2006;36:121-30.